NO2753788T3 - - Google Patents

Info

Publication number
NO2753788T3
NO2753788T3 NO12829698A NO12829698A NO2753788T3 NO 2753788 T3 NO2753788 T3 NO 2753788T3 NO 12829698 A NO12829698 A NO 12829698A NO 12829698 A NO12829698 A NO 12829698A NO 2753788 T3 NO2753788 T3 NO 2753788T3
Authority
NO
Norway
Application number
NO12829698A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50933526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2753788(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2753788T3 publication Critical patent/NO2753788T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO12829698A 2013-05-10 2012-04-05 NO2753788T3 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361822139P 2013-05-10 2013-05-10

Publications (1)

Publication Number Publication Date
NO2753788T3 true NO2753788T3 (no) 2018-06-16

Family

ID=50933526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12829698A NO2753788T3 (no) 2013-05-10 2012-04-05

Country Status (28)

Country Link
US (5) US9040584B2 (no)
EP (3) EP3124015B1 (no)
JP (2) JP5930568B1 (no)
KR (4) KR102098987B1 (no)
CN (2) CN109966240A (no)
AU (3) AU2014262495B9 (no)
BR (1) BR112015028290A2 (no)
CA (1) CA2907721C (no)
CL (1) CL2015003270A1 (no)
CR (1) CR20150652A (no)
CY (1) CY1118654T1 (no)
DK (2) DK2863886T3 (no)
ES (2) ES2604160T3 (no)
HK (1) HK1213200A1 (no)
HU (2) HUE037405T2 (no)
IL (2) IL240807A (no)
MX (2) MX347969B (no)
MY (1) MY183193A (no)
NO (1) NO2753788T3 (no)
NZ (1) NZ712784A (no)
PH (1) PH12015502503B1 (no)
PL (2) PL2863886T3 (no)
PT (2) PT2863886T (no)
RU (1) RU2635864C2 (no)
SG (2) SG11201600068WA (no)
SI (1) SI2863886T1 (no)
WO (1) WO2014183045A2 (no)
ZA (1) ZA201507702B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
US9089579B2 (en) 2011-01-19 2015-07-28 Topokine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
NO2753788T3 (no) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
EP3288559B1 (en) 2015-04-30 2020-06-24 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
WO2016200817A1 (en) * 2015-06-09 2016-12-15 Thesan Pharmaceuticals, Inc. Beta-naphthoisoflavones, compositions containing, and uses of, same
US20180179174A1 (en) * 2015-06-23 2018-06-28 Thesan Pharmaceuticals, Inc. 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
CA2990856A1 (en) * 2015-06-23 2016-12-29 Thesan Pharmaceuticals, Inc. 12h-benzo[a]xanthen-12-ones, compositions containing, and uses of, same
WO2017075289A1 (en) 2015-10-27 2017-05-04 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
CN107773758B (zh) * 2016-08-31 2021-02-26 程辉 一种用于消除皮下脂肪沉积的组合物及其应用
US20220031631A1 (en) * 2018-09-19 2022-02-03 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3713551B1 (en) 2018-10-16 2023-06-07 Polithera, Inc. Alcohol-based compositions and uses thereof
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
JP6855026B1 (ja) * 2020-11-09 2021-04-07 東亜薬品株式会社 タフルプロスト点眼液
US20230012087A1 (en) * 2021-07-12 2023-01-12 Ocusoft, Inc. Skin moisturizing compositions

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
EP0302147A1 (en) 1987-08-03 1989-02-08 The Procter & Gamble Company Topical tanning compositions
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
DE03014533T1 (de) 1988-09-06 2004-07-15 Pharmacia Ab Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5011062A (en) 1990-05-09 1991-04-30 Delco Electronics Corporation Ultrasonic welding mask
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
RU2157689C2 (ru) 1996-07-24 2000-10-20 Панацея Биотек Лтд. Фармацевтические композиции терапевтического антивоспалительного и болеутоляющего средства для местного нанесения и способ их получения
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
WO1998033497A1 (en) 1997-02-04 1998-08-06 Johnstone Murray A Method of enhancing hair growth
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
WO1999032441A1 (en) 1997-12-22 1999-07-01 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
DE60135633D1 (de) 2000-02-10 2008-10-16 Massachusetts Eye & Ear Infirm Photodynamische therapie zur behandlung von augenerkrankungen
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
EA006556B1 (ru) 2001-03-27 2006-02-24 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот
GB0202159D0 (en) 2002-01-30 2002-03-20 Sensor Highway Ltd OPtical time domain reflectometry
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
JP4387639B2 (ja) * 2002-07-16 2009-12-16 久光製薬株式会社 経皮吸収製剤
US6864282B2 (en) 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
ATE539756T1 (de) 2002-10-23 2012-01-15 Sucampo Ag Prostaglandinsubstanzen für die behandlung von fettsucht
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
KR101086147B1 (ko) 2003-03-21 2011-11-25 넥스메드 홀딩스 인코포레이티드 조루증 치료용 조성물 및 치료 방법
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050058614A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
ES2660172T3 (es) 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
EP1848541A4 (en) 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
CN102293774A (zh) 2005-03-31 2011-12-28 旭硝子株式会社 前列腺素F2α衍生物的应用
WO2007011743A2 (en) 2005-07-14 2007-01-25 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
WO2007011846A2 (en) * 2005-07-18 2007-01-25 Soundquest, Inc. In-ear auditory device and methods of using same
EP2452686A3 (en) 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US9393218B2 (en) 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
RU2325912C1 (ru) * 2006-09-06 2008-06-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция противовоспалительного и антимикробного действия в форме мази на гидрофобной основе для лечения кожных заболеваний (варианты)
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2008120249A1 (en) 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CN101427993A (zh) 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 前列腺素微乳凝胶制剂及其制备方法
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
EP2640350B1 (en) 2010-11-18 2018-09-26 Steven Yoelin Compositions and methods for hair growth
WO2013172838A1 (en) 2012-05-17 2013-11-21 Steven Yoelin Compositions and methods for hair growth
US9089579B2 (en) 2011-01-19 2015-07-28 Topokine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
RU2599249C2 (ru) 2011-02-14 2016-10-10 Аллерган, Инк. Композиции и способы применения сложноэфирных производных биматопроста
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
JP2012250950A (ja) * 2011-06-06 2012-12-20 Santen Pharmaceut Co Ltd アデノシン誘導体とプロスタグランジン類の組合せ剤
MX2014000781A (es) * 2011-07-20 2014-04-30 Allergan Inc Dosis combinada fija de bimatoprost y brimonidina.
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
KR20140043562A (ko) 2012-09-24 2014-04-10 한국콜마주식회사 무복계면 라타노프로스트 및 그 제조방법
MX2015006390A (es) 2012-11-21 2015-08-05 Topokine Therapeutics Inc Metodos y composiciones para incrementar localmente la grasa corporal.
NO2753788T3 (no) 2013-05-10 2018-06-16
WO2014186504A1 (en) * 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen

Also Published As

Publication number Publication date
CN109966240A (zh) 2019-07-05
PT3124015T (pt) 2018-05-10
PT2863886T (pt) 2016-12-02
EP2863886B1 (en) 2016-08-24
KR20150133865A (ko) 2015-11-30
IL251448B (en) 2021-01-31
KR101651450B1 (ko) 2016-08-26
DK2863886T3 (en) 2016-12-12
PL3124015T3 (pl) 2018-09-28
WO2014183045A2 (en) 2014-11-13
MY183193A (en) 2021-02-18
CA2907721A1 (en) 2014-11-13
EP3124015A1 (en) 2017-02-01
PH12015502503A1 (en) 2016-02-22
JP5930568B1 (ja) 2016-06-08
AU2019250230A1 (en) 2019-11-07
AU2014262495B2 (en) 2019-07-18
US20180200372A1 (en) 2018-07-19
US20150231251A1 (en) 2015-08-20
EP3395328A1 (en) 2018-10-31
PH12015502503B1 (en) 2016-02-22
RU2635864C2 (ru) 2017-11-16
KR20210040180A (ko) 2021-04-12
US20150105462A1 (en) 2015-04-16
JP2016135810A (ja) 2016-07-28
EP2863886A2 (en) 2015-04-29
MX347969B (es) 2017-05-18
CN105209015A (zh) 2015-12-30
HK1213200A1 (zh) 2016-06-30
SI2863886T1 (sl) 2017-01-31
HUE030977T2 (en) 2017-06-28
ZA201507702B (en) 2016-11-30
KR20160102326A (ko) 2016-08-29
AU2014262495B9 (en) 2019-07-25
DK3124015T3 (en) 2018-06-06
JP2016518416A (ja) 2016-06-23
SG11201600068WA (en) 2016-02-26
ES2604160T3 (es) 2017-03-03
AU2021221900A1 (en) 2021-09-23
KR20200037458A (ko) 2020-04-08
MX2015015535A (es) 2016-02-09
ES2670323T3 (es) 2018-05-30
HUE037405T2 (hu) 2018-08-28
IL251448A0 (en) 2017-05-29
SG10201604659QA (en) 2016-07-28
EP3124015B1 (en) 2018-03-28
US10556012B2 (en) 2020-02-11
MX2020002881A (es) 2020-07-22
CR20150652A (es) 2016-06-01
US9040584B2 (en) 2015-05-26
IL240807A (en) 2017-04-30
CY1118654T1 (el) 2017-07-12
CN105209015B (zh) 2018-11-20
US20220152206A1 (en) 2022-05-19
BR112015028290A2 (pt) 2017-07-25
AU2014262495A1 (en) 2015-10-22
NZ730201A (en) 2021-01-29
WO2014183045A3 (en) 2015-01-29
PL2863886T3 (pl) 2017-03-31
NZ712784A (en) 2017-03-31
KR102098987B1 (ko) 2020-04-08
CA2907721C (en) 2016-02-23
RU2015141767A (ru) 2017-04-06
US9849179B2 (en) 2017-12-26
US20200282059A1 (en) 2020-09-10
CL2015003270A1 (es) 2016-07-08

Similar Documents

Publication Publication Date Title
BR112014017635A2 (no)
BR112014017614A2 (no)
BR112014017625A2 (no)
BR112014017592A2 (no)
BR112014017659A2 (no)
BR112014017646A2 (no)
BR112014017638A2 (no)
BR112014017607A2 (no)
NO2753788T3 (no)
BR112013027865A2 (no)
BR112014017634A2 (no)
BR112014019903A2 (no)
BR112014017609A2 (no)
BR112014017644A2 (no)
BR112014017647A2 (no)
BR112014017588A2 (no)
BR112014025790A2 (no)
BR112014017618A2 (no)
BR112014013184A8 (no)
BR112014017630A2 (no)
BR112014017652A2 (no)
BR112014025138A2 (no)
BR112014017621A2 (no)
BR112014017622A2 (no)
BR112014017627A2 (no)